Clinical Trials Sponsored by BioEclipse Therapeutics
Total 6253 results
-
BIND TherapeuticsCompletedCancer | Metastatic Cancer | Solid TumorsUnited States
-
United TherapeuticsWithdrawnPulmonary Fibrosis | Pulmonary HypertensionUnited States
-
Acorda TherapeuticsCompletedIschemic StrokeUnited States
-
Vicus TherapeuticsUnknown
-
Noven TherapeuticsCompleted
-
Intarcia TherapeuticsCompleted
-
Proteon TherapeuticsCompletedChronic Kidney DiseaseUnited States
-
Aerpio TherapeuticsCompletedDiabetic Macular Edema (DME)United States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Puerto Rico
-
Alaunos TherapeuticsCompletedBreast Cancer Nos Metastatic RecurrentUnited States
-
Alaunos TherapeuticsCompleted
-
Pulse TherapeuticsTerminated
-
Summit TherapeuticsCompletedDuchenne Muscular DystrophyUnited Kingdom
-
Halozyme TherapeuticsCompletedDiabetes Mellitus, Type 2United States
-
Guided TherapeuticsUnknown
-
Halozyme TherapeuticsCompleted
-
Chelsea TherapeuticsCompletedIntradialytic HypotensionUnited States
-
Acorda TherapeuticsCompletedCerebral Palsy (CP)United States
-
Ocera TherapeuticsCompletedMild Hepatic EncephalopathyUnited States
-
Ocera TherapeuticsCompletedIrritable Bowel SyndromeUnited States, Belgium
-
Mateon TherapeuticsTerminatedAnaplastic Thyroid CancerUnited States, India, Belarus, Bulgaria, Egypt, Israel, Italy, Poland, Romania, Russian Federation, Ukraine, United Kingdom
-
Chelsea TherapeuticsTerminatedStudy To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome (CFS201)Chronic Fatigue Syndrome | Orthostatic Hypotension | Neurally Mediated Hypotension | Neurogenic Orthostatic HypotensionUnited States
-
Ocera TherapeuticsCompletedIntestinal Fistula | Inflammatory Bowel DiseaseUnited States, Israel, Canada, United Kingdom, Germany, Belgium, Hungary, France, Austria, Czech Republic, Netherlands, Poland
-
Ocera TherapeuticsCompletedHepatic EncephalopathyUnited States
-
Chelsea TherapeuticsCompletedMultiple System Atrophy | Neurogenic Orthostatic Hypotension | Dopamine Beta Hydroxylase Deficiency | Non-Diabetic Autonomic NeuropathyUnited States, Australia, Canada, New Zealand
-
Celldex TherapeuticsTerminatedC3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type IIUnited States
-
Sorbent TherapeuticsCompleted
-
Halozyme TherapeuticsCompleted
-
Amicus TherapeuticsCompleted
-
Cytori TherapeuticsCompletedMyocardial Infarction | Coronary Disease | Cardiovascular Disease | Coronary ArteriosclerosisSpain, Netherlands
-
Aeris TherapeuticsTerminatedPulmonary EmphysemaGermany, Israel
-
Alaunos TherapeuticsUnknownMultiple MyelomaUnited States
-
Aeris TherapeuticsWithdrawnEmphysema | Chronic Obstructive Pulmonary Disease (COPD)
-
Alaunos TherapeuticsUnknownHEPATOCELLULAR CARCINOMAUnited States
-
Sorbent TherapeuticsCompletedHeart FailureUnited States
-
Alaunos TherapeuticsCompletedMelanomaUnited States
-
Alaunos TherapeuticsCompletedSoft Tissue SarcomaUnited States, France, Spain, Belgium, Argentina, Colombia, Israel, India, Romania, Australia, Canada, Singapore, Russian Federation, Brazil, Chile, Germany, Guatemala, Italy, Panama, Poland, United Kingdom
-
Argos TherapeuticsCompleted
-
United TherapeuticsTerminatedPeripheral Vascular Disease | Critical Limb Ischemia | Foot Ulcers | Rest Leg PainUnited States
-
Argos TherapeuticsCompleted
-
Allon TherapeuticsCompletedProgressive Supranuclear PalsyUnited States, Australia, France, Canada, Germany, United Kingdom
-
Intarcia TherapeuticsWithdrawnType 2 DiabetesUnited States
-
Intarcia TherapeuticsWithdrawnType 2 DiabetesUnited States
-
Yaupon TherapeuticsCompletedMycosis FungoidesUnited States
-
Allon TherapeuticsCompletedMild Cognitive Impairment, So StatedUnited States
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Pathfinder TherapeuticsTerminatedLiver CancerUnited States
-
Alaunos TherapeuticsCompletedAdvanced Solid TumorsUnited States
-
Alaunos TherapeuticsUnknownAdvanced Solid TumorsUnited States
-
Alaunos TherapeuticsUnknownAdvanced CancerUnited States